{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T21:14:02Z","timestamp":1717276442597},"reference-count":26,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2009,8,4]],"date-time":"2009-08-04T00:00:00Z","timestamp":1249344000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cathet Cardio Intervent"],"published-print":{"date-parts":[[2009,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:styled-content>Background:<\/jats:styled-content> No data are available on the long term efficacy of abciximab bolus\u2010only with aspirin and clopidogrel pretreatment and systematic coronary stenting. Our objective was to evaluate the 3\u2010year clinical outcomes in the EASY trial. <jats:styled-content>Methods:<\/jats:styled-content> After a bolus of abciximab (0.25 mg\/kg) and uncomplicated transradial coronary stenting, 1,005 patients were randomized either to same\u2010day home discharge and no infusion (bolus\u2010only group, <jats:italic>n<\/jats:italic> = 504) or to overnight hospitalization and 12 hours abciximab infusion (bolus + infusion group, <jats:italic>n<\/jats:italic> = 501). In contrast, 343 patients were not randomized after stenting for safety reasons and received abciximab bolus and infusion (not\u2010randomized group). The rate of major adverse cardiovascular events (MACE), including death, myocardial infarction (MI) and target vessel revascularization (TVR) after percutaneous coronary intervention (PCI) was evaluated. <jats:styled-content>Results:<\/jats:styled-content> Up to 3 years, the incidence of MACE remained similar in the two randomized groups, 14% in bolus\u2010only vs. 17% in bolus + infusion (<jats:italic>P<\/jats:italic> = 0.38). Similar efficacy was observed in subgroups analysis including higher\u2010risk patients such as those with diabetes, unstable angina or non\u2010ST elevation MI. Conversely, the incidence of MACE remained significantly higher in patients not\u2010randomized post\u2010PCI at all time intervals (<jats:italic>P<\/jats:italic> &lt; 0.0001). The difference in outcomes between randomized and not\u2010randomized patients was mostly accounted by the higher rates of MI, TVR as survival rate remained similar. <jats:styled-content>Conclusion:<\/jats:styled-content> In patients pretreated with aspirin and clopidogrel and undergoing uncomplicated coronary artery stenting, abciximab bolus\u2010only was associated with similar outcomes compared with bolus followed by infusion, up to 3 years after PCI. Conversely, patients with suboptimal results or clinical complications during PCI remained at higher risk of late revascularization or MI. \u00a9 2009 Wiley\u2010Liss, Inc.<\/jats:p>","DOI":"10.1002\/ccd.22235","type":"journal-article","created":{"date-parts":[[2009,8,4]],"date-time":"2009-08-04T15:56:02Z","timestamp":1249401362000},"page":"1010-1016","source":"Crossref","is-referenced-by-count":7,"title":["Long term efficacy of abciximab bolus\u2010only compared to abciximab bolus and infusion after transradial coronary stenting"],"prefix":"10.1002","volume":"74","author":[{"given":"Rodrigo","family":"Bagur","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier F.","family":"Bertrand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josep","family":"Rod\u00e9s\u2010Cabau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c9ric","family":"Larose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St\u00e9phane","family":"Rinfret","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Can M.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernard","family":"Noel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert De","family":"Larochelli\u00e8re","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Poirier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Costerousse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louis","family":"Roy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,9,14]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199808133390704"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199805213382102"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)03400-0"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200106213442501"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199404073301402"},{"key":"e_1_2_7_7_2","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1001\/jama.1997.03550060055036","article-title":"Long\u2010term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of platelet IIb\/IIIa inhibition for prevention of ischemic complication","volume":"278","author":"Topol EJ","year":"1997","journal-title":"JAMA"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(02)01145-2"},{"issue":"4","key":"e_1_2_7_9_2","doi-asserted-by":"crossref","first-page":"79S","DOI":"10.1016\/S0735-1097(02)02831-0","article-title":"Short\u2010 and long\u2010term oral antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention","volume":"41","author":"Mehta SR","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)05701-4"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.288.19.2411"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000051362.96946.15"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.638627"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2008.02.006"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/ccd.21662"},{"key":"e_1_2_7_16_2","first-page":"77","article-title":"The transulnar approach for coronary intervention: A safe alternative to transradial approach in selected patients","volume":"17","author":"Mangin L","year":"2005","journal-title":"J Invasive Cardiol"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(01)01702-8"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0828-282X(07)71012-7"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2008.08.023"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcin.2008.05.007"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(00)00554-4"},{"key":"e_1_2_7_22_2","first-page":"487","article-title":"High\u2010dose, single\u2010bolus eptifibatide: A safe and cost\u2010effective alternative to conventional glycoprotein IIb\/IIIa inhibitor use for elective coronary interventions","volume":"18","author":"Fischell TA","year":"2006","journal-title":"J Invasive Cardiol"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2008.04.019"},{"key":"e_1_2_7_24_2","first-page":"53","article-title":"High\u2010dose tirofiban administered as bolus\u2010only during percutaneous coronary intervention","volume":"20","author":"Marmur JD","year":"2008","journal-title":"J Invasive Cardiol"},{"key":"e_1_2_7_25_2","first-page":"521","article-title":"Bolus\u2010only platelet glycoprotein IIb\u2010IIIa inhibition during percutaneous coronary intervention","volume":"18","author":"Marmur JD","year":"2006","journal-title":"J Invasive Cardiol"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/ccd.21773"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2008.09.010"}],"container-title":["Catheterization and Cardiovascular Interventions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fccd.22235","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ccd.22235","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,13]],"date-time":"2023-11-13T22:21:02Z","timestamp":1699914062000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ccd.22235"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9,14]]},"references-count":26,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["10.1002\/ccd.22235"],"URL":"https:\/\/doi.org\/10.1002\/ccd.22235","archive":["Portico"],"relation":{},"ISSN":["1522-1946","1522-726X"],"issn-type":[{"value":"1522-1946","type":"print"},{"value":"1522-726X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,9,14]]}}}